EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Open Access · CC BY-NC 4.0

Benefit of selinexor dose reduction on outcomes with selinexor, bortezomib and dexamethasone in patients with lenalidomide‐refractory multiple myeloma: Subgroup analysis of the BOSTON trial

Sosana Delimpasi iD, Ivan Špička, Jason P Butler, Don A Stevens, Mercedes Gironella Mesa, Ceri Bygrave iD, Giovanni Marino Merlo, Charles la Porte, Meletios A Dimopoulos

British Journal of Haematology · 2026-06 · 208 (6) · 2260-2264

DOI: 10.1111/bjh.70479 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift British Journal of Haematology, online erschienen am 14.04.2026. Verfasst von Sosana Delimpasi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Evangelismos Hospital, Athens, Greece. Hauptthemen laut MEDLINE: Multiple Myeloma, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Menarini Group.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaAntineoplastic Combined Chemotherapy ProtocolsHumansDexamethasoneLenalidomideBortezomibTriazolesHydrazinesFemaleMaleMiddle AgedQuality of LifeTreatment OutcomeDrug Resistance, NeoplasmAged

Stichwörter der Autor:innen

BOSTONdose reductionlenalidomide‐refractorymultiple myelomaselinexor

Substanzen

DexamethasoneLenalidomideBortezomibselinexorTriazolesHydrazines

Autor:innen und Institutionen

  • Evangelismos Hospital, Athens, Greece.
  • First Department of Medicine, Department of Hematology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.
  • Bone Marrow Transplant Unit, Royal Brisbane and Women's Hospital, Herston, Queensland, Australia.
  • Norton Cancer Institute, Louisville, Kentucky, USA.
  • Department of Hematology, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
  • University Hospital of Wales, Cardiff, UK.

ORCID-Profile: Sosana Delimpasi, Ceri Bygrave

Förderung

  • Menarini Group

Zitieren

APA

Delimpasi, S., Špička, I., Butler, J. P., Stevens, D. A., Mesa, M. G., Bygrave, C., Merlo, G. M., la Porte, C., & Dimopoulos, M. A. (2026). Benefit of selinexor dose reduction on outcomes with selinexor, bortezomib and dexamethasone in patients with lenalidomide‐refractory multiple myeloma: Subgroup analysis of the BOSTON trial. British Journal of Haematology, 208(6), 2260-2264. https://doi.org/10.1111/bjh.70479

Vancouver

Delimpasi S, Špička I, Butler JP, Stevens DA, Mesa MG, Bygrave C, et al. Benefit of selinexor dose reduction on outcomes with selinexor, bortezomib and dexamethasone in patients with lenalidomide‐refractory multiple myeloma: Subgroup analysis of the BOSTON trial. British Journal of Haematology. 2026;208(6):2260-2264. doi:10.1111/bjh.70479

BibTeX
@article{Delimpasi2026,
  author = {Delimpasi, Sosana and Špička, Ivan and Butler, Jason P and Stevens, Don A and Mesa, Mercedes Gironella and Bygrave, Ceri and Merlo, Giovanni Marino and la Porte, Charles and Dimopoulos, Meletios A},
  title = {Benefit of selinexor dose reduction on outcomes with selinexor, bortezomib and dexamethasone in patients with lenalidomide‐refractory multiple myeloma: Subgroup analysis of the BOSTON trial},
  journal = {British Journal of Haematology},
  year = {2026},
  volume = {208},
  number = {6},
  pages = {2260--2264},
  doi = {10.1111/bjh.70479}
}
Kostenlos starten →